Regenxbio Inc (RGNX) Implied Volatility Current

Tracking RGNX implied volatility helps you identify when options premiums on Regenxbio Inc are historically cheap or expensive, and where the best trades are hiding. Regenxbio Inc implied volatility reflects the market's expectation of future price movement: when RGNX IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor Regenxbio Inc's implied volatility current levels in real time and filter for high-probability trades.

Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For RGNX, tracking metrics like RGNX IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on RGNX signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage.

REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.

Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where RGNX implied volatility sits today versus where it has been. Our scanner ranks Regenxbio Inc implied volatility against its historical range, surfaces extremes in RGNX IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether Regenxbio Inc IV is rich or cheap — measure it, then act on it.